ZA959388B - Compositions comprising carbazoles and cyclodextrins - Google Patents

Compositions comprising carbazoles and cyclodextrins

Info

Publication number
ZA959388B
ZA959388B ZA959388A ZA959388A ZA959388B ZA 959388 B ZA959388 B ZA 959388B ZA 959388 A ZA959388 A ZA 959388A ZA 959388 A ZA959388 A ZA 959388A ZA 959388 B ZA959388 B ZA 959388B
Authority
ZA
South Africa
Prior art keywords
carbazoles
cyclodextrins
compositions
Prior art date
Application number
ZA959388A
Inventor
Jean-Louis Mesens
Herman M J Van Cauteren
Peter Putteman
Jozef Peeters
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA959388B publication Critical patent/ZA959388B/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA959388A 1994-11-07 1995-11-06 Compositions comprising carbazoles and cyclodextrins ZA959388B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203242 1994-11-07

Publications (1)

Publication Number Publication Date
ZA959388B true ZA959388B (en) 1997-05-06

Family

ID=8217355

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA959388A ZA959388B (en) 1994-11-07 1995-11-06 Compositions comprising carbazoles and cyclodextrins

Country Status (5)

Country Link
AU (1) AU3846395A (en)
IL (1) IL115885A0 (en)
TR (1) TR199501376A2 (en)
WO (1) WO1996014090A1 (en)
ZA (1) ZA959388B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
US6683100B2 (en) 1999-01-19 2004-01-27 Novartis Ag Organic compounds
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
AU2002214296C1 (en) 2000-11-17 2006-04-13 Takeda Pharmaceutical Company Limited Novel imidazole derivatives, production method thereof and use thereof
AU2002214320A1 (en) 2000-11-20 2002-05-27 Takeda Chemical Industries Ltd. Imidazole derivatives, process for their preparation and their use
ATE440096T1 (en) 2000-12-08 2009-09-15 Takeda Pharmaceutical SUBSTITUTED THIAZOLE DERIVATIVES WITH 3-PYRIDYL GROUPS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
UA105794C2 (en) 2009-06-26 2014-06-25 Новартіс Аг 1,3-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES AS Cyp17 INHIBITORS
CA2779309A1 (en) * 2009-10-23 2011-04-28 Health Research, Inc. Method for treating androgen receptor positive cancers
EP2600855A2 (en) 2010-08-04 2013-06-12 Pellficure Pharmaceuticals, Inc. Combination therapy for the treatment of prostate carcinoma
EP2627648A1 (en) 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
MX359399B (en) 2011-04-28 2018-09-27 Novartis Ag 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS.
AU2014241816B9 (en) 2013-03-14 2019-02-14 Pellficure Pharmaceuticals Inc. Novel therapy for prostate carcinoma
CA2960750A1 (en) 2014-09-12 2016-03-17 Pellficure Pharmaceuticals, Inc. Compositions and methods for treatment of prostate carcinoma
AU2017350690A1 (en) 2016-10-24 2019-06-13 Pellficure Pharmaceuticals Inc. Pharmaceutical compositions of 5-hydroxy-2-methylnaphthalene-1, 4-dione

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310635D0 (en) * 1993-05-21 1993-07-07 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
WO1996014090A1 (en) 1996-05-17
AU3846395A (en) 1996-05-31
IL115885A0 (en) 1996-01-31
TR199501376A2 (en) 1996-06-21

Similar Documents

Publication Publication Date Title
PL314956A1 (en) Siclicium-sodium-calcium glass compositions and their application
IL115891A0 (en) Hemorrhoidial compositions and their use
PL327659A1 (en) Disinfecting compositions and surface disinfecting methods
GB9616411D0 (en) Shampoo compositions and method
PL332699A1 (en) Immunomodulation methods and compositions
IL126546A (en) Composition comprising aryl-piperazinyl-hetrocyclic salts and cyclodextrin
GB9525977D0 (en) Perfluoroelastomeric compositions and methods
AU3641597A (en) Methods and compositions comprising r-ibuprofen
GB9525812D0 (en) Composition and use
AU2972597A (en) Compositions and uses thereof
ZA959388B (en) Compositions comprising carbazoles and cyclodextrins
PL331423A1 (en) Muporocin and chlorohexidrin containing compositions
ZA9510792B (en) Polymerization compounds and compositions
GB9624501D0 (en) Insecticial compositions and method
HUP9802997A3 (en) Antisudorific and/or deodorant compositions
US5478356B1 (en) Cyanoimides and compositions useful for bleaching
AU3674595A (en) Antianemic agent containing iron and difructose
IL112564A0 (en) 1-beta-methyl-carbapenems and compositions containing them
PL331523A1 (en) Azolotrizines and azolopyrimidines
AUPO982097A0 (en) Methods and compositions for use therein
AU691690B2 (en) Acrolein-releasing composition and use thereof
HUP9900068A3 (en) Fuse-switch and/or fuse-disconnector
AU1468797A (en) Ghrh-rp compositions and methods
AU3227295A (en) Oil treatment and compositions therefor
AU3776495A (en) Aryloxycycloalkenyl and aryloxyiminocycloalkenylhydroxyureas